pcn poster

Posters

The Association Between COMT Genotype and Bupropion Treatment Response in Outpatients With Major Depressive Disorder

Background: Studies examining treatment responses to antidepressants based on genotype have produced inconsistent findings. Although catechol-O-methyltransferase (COMT) metabolizes catech...

Jeanne Carroll , BA, RN, CCRC;

Michael J. Mirro , MD, FACC;

Jay Fawver , MD;

Mindy Flanagan , PhD;

11/22/2019

Use of Supportive Medication for Opioid Withdrawal Syndrome in a Randomized, Placebo-Controlled Trial of Lofexidine

Introduction: Abrupt discontinuation of opioids after chronic use can result in severe, distressing symptoms that result from central noradrenergic hyperactivity. Avoidance of opioid with...

Mark Pirner , MD, PhD;

Thomas Clinch , MS;

11/22/2019

Adverse Events Affecting Readiness for Discharge From the Clinical Setting After Esketamine Nasal Spray Administration

Objective: To describe clinical findings in patients considered not ready for discharge from clinical sites 2 hours after administration of esketamine nasal spray (ESK).

Leah Aluisio , PhD;

David Williamson , PhD, MBA;

Ella Daly , MB, BCh, BAO;

Michelle Han , PharmD;

Sheldon Preskorn , MD;

Jagadish Gogate , PhD;

H. Lynn Starr , MD, FAAP;

Andrew Winokur , MD, PhD;

11/22/2019

The NeuroStar Outcomes Registry

NeuroStar® Advanced Therapy System is an effective acute treatment for patients with Major Depressive Disorder (MDD). To further understand the efficacy of the NeuroStar in a clinical set...

Todd Hutton , MD;

Miriam Mina , BS;

Karen Heart , BS, MBA;

11/22/2019

Development of a Decision Aid in Support of Shared Decision-Making for Treatment-Resistant Depression

Shared decision-making (SDM) involves patients and clinicians choosing treatment together. SDM in mental health is hampered by lack of well-developed supporting tools. We describe an evid...

Luis Allen , MD;

Jacqueline Pesa , PhD, MPH;

Martha Rhodes ;

Alicia Shillington , PhD, MPH;

Richard Shelton , MD;

Margaret Holmes-Rovner , PhD;

David Williamson , PhD, MBA;

Phyllis Foxworth , BS;

Scott Langenecker , PhD;

11/22/2019

Patient Characterization Based on Missed Dose Surveys in Digital Medicine

Introduction: Digital medicine consists of the integration of active pharmaceuticals and wearable/ingestible sensors combined with mobile and web-based tools to improve effectiveness of c...

Zahra Heidary , PhD;

Jonathan Knights , PhD;

11/22/2019

The Impact of Second-Generation Antipsychotic Side-Effects on Functioning From a Schizophrenia Patient Perspective: A Global Patient Centered Survey

Background: The impact of side effects (SEs) of second-generation antipsychotics (SGAs) on patients’ physical and emotional functioning and overall quality of life (QoL) is insufficiently...

Mallik Greene , PhD, DBA;

Laetitia Bouerat Duvold , PhD;

Catherine Weiss , PhD;

William Lenderking , PhD;

Stine Rasmussen Meehan , PhD;

H. Lundbeck ;

Huda Shalhoub , PhD;

Carla Dias-Barbosa , MSc;

Jun Chen , MS, MSc;

Andrea Schulz , MA;

Ann Hartry , PhD;

11/22/2019

Medication Preference for Injectable Versus Oral Antipsychotics in Patients With Schizophrenia: Results From a Patient-Reported Questionnaire From a Double-Blind Randomized Controlled Study

Introduction: Assessing factors that determine patients’ preferences for long-acting injectable (LAI) or oral antipsychotics could help reduce potential barriers to LAI use in schizophren...

Clifton Blackwood , MD;

Panna Sanga , MD;

Isaac Nuamah , PhD;

Arun K. Singh , MD, PhD, MCh, MNAMS;

Alexander Keenan , MA, MS, MD;

Srihari Gopal , MD;

Maju Mathews , MD;

11/22/2019

Predicting Incident Treatment-Resistant Depression: A Model Designed for Health Care Systems

Background: Treatment resistant depression (TRD) is burdensome to health systems. Earlier identification of at-risk patients may reduce clinical inertia and improve outcomes.

Jacqueline Pesa , PhD, MPH;

Charles Ruetsch , PhD;

Joshua Liberman , PhD;

Tigwa Davis , PhD;

Sara Heverly-Fitt , PhD;

John Verbanac , PhD;

Wing Chow , PharmD, MPH;

11/22/2019

Exploring Patient Experiences Taking Adjunctive Brexpiprazole for Major Depressive Disorder (MDD): Post-hoc Analysis of Exit Interview Data

Background: The efficacy and safety of adjunctive brexpiprazole, a serotonin–dopamine activity modulator, has been demonstrated in clinical studies in adults with MDD and inadequate respo...

Michelle Brown , PhD;

Catherine Gupta , PhD;

Dana DiBenedetti , PhD;

Michael Thase , MD;

Zahinoor Ismail , MD;

Roger McIntyre , MD, FRCPC;

Catherine Weiss , PhD;

Stine Rasmussen Meehan , PhD;

H. Lundbeck ;

11/22/2019

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Rapid Refresh

Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics

04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...

Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...

Andrew Penn, MS, PMHNP, and...

04/11/2024

Psych Congress NP Institute

Rapid Refresh

Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder

04/10/2024

Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...

Amber Hoberg, PMHNP-BC,...

04/10/2024

Psych Congress NP Institute

Clinical Pearls

Tolerability Testing in Long-Acting Injectable Prescriptions

04/03/2024

Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.

Posters

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

Sign Up

Specialties

Events

Year Round Education

HMP Global Products